COMMUNIQUÉS West-GlobeNewswire

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
18/05/2026
– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma – – [...]
Ipsen - April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital
18/05/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Capitol Hill Briefing To Spotlight Critical Health Care Services for Adults With Communication Disorders
18/05/2026
ASHA Collaborates With Co-Chairs of the Unified Voices Caucus, Reps. Kat Cammack and Troy Carter, for May 20 Event Rockville, Md., May 18, 2026 (GLOBE NEWSWIRE) -- In recognition of National Speech-Language-Hearing [...]
Disclosure of transparency notifications from BlackRock, Inc.
18/05/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 18 May 2026 – 6 PM CET Disclosure of transparency notifications from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of [...]
Carbios annonce une évolution de sa gouvernance et la nomination de Benoît Grenot en qualité de Directeur Général.
18/05/2026
Clermont-Ferrand (France), 18 mai 2026 (17h45 CEST). Carbios (Euronext Growth Paris : ALCRB) annonce une évolution de sa gouvernance. Ayant à 64 ans fait part de sa volonté de partir à la retraite, Vincent Kamel [...]
Letter to Shareholders from CEO Dr. Ryan Saadi
18/05/2026
WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). Dear Shareholders, Since Tevogen’s 2024 public listing, we have remained focused on building a [...]
Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference
18/05/2026
SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy [...]
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
18/05/2026
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Alpha Tau to Participate in May Investor Conferences
18/05/2026
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
18/05/2026
ORANGE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami, Florida, on [...]
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
18/05/2026
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to [...]
Novastra Therapeutics Appoints Chief Financial Officer as Company Advances Lead Candidate Toward Global Clinical Development
18/05/2026
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Novastra Therapeutics , a clinical-stage biotech company developing a novel category of cancer immune therapy, today announced the appointment of Jarett Poll as [...]
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
18/05/2026
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics [...]
ORAGENICS PROVIDES INVESTOR UPDATE
18/05/2026
A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has continued to [...]
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
18/05/2026
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to [...]
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
18/05/2026
Offering oversubscribed through full exercise of underwriters’ option, supported by strong investor demand Total gross proceeds increased to $57.5 million Offering consisted solely of common stock Proceeds expected to [...]
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
18/05/2026
Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vitiligo, fueling [...]
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
18/05/2026
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
18/05/2026
Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany through the EU [...]

Pages